Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sema-Mood
2024-511734-13-04Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD), Overweight and obesity comparing Semaglutide (Wegovy) add-on with Placebo add-on (2 arms). Planned start May 2025; status: authorised.
02
Drugs
03
Conditions
major depressive disorder (MDD)Overweightobesity
Beyond the preview
Go deeper on 2024-511734-13-04.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511734-13-04.